News Articles

European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD, the First New Treatment in Decades for Adults... CAMBRIDGE, Mass. and OSAKA, Japan -Tuesday 12 February 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) extended the current marketing authorization of ADCETRIS (brentuximab vedotin) to include treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin...

Takeda Announces Results from First-of-Its-Kind Phase IIIb/IV Trial PROPEL – a Randomized PK-Guided Prophylaxis... -Thursday 7 February 2019

The PROPEL study compared the safety and efficacy of ADYNOVATE® [Antihemophilic Factor [Recombinant], PEGylated] following pharmacokinetic (PK)-guided prophylaxis, targeting two different factor VIII trough levels The novel design of the study was built upon preliminary data indicating...

Takeda Reports Third Quarter FY2018 Results -Monday 4 February 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): Underlying Revenue +4.8% year-to-date with growth of prescription drug portfolio in all regions Solid Underlying Revenue growth of +4.8%, with continued strong momentum from Takeda's Growth Drivers...

Takeda Scoops Prestigious Global Top Employers® Award for Second Year Running -Friday 1 February 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited [TOKYO: 4502 / NYSE: TAK], (“Takeda”) today announced it has become part of a select group of only 12 to receive global Top Employer® status for 2019. Established over 25 years ago, award certification is given annually by the Top...

Takeda’s Dengue Vaccine Candidate Meets Primary Endpoint in Pivotal Phase 3 Efficacy Trial -Friday 1 February 2019  

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited [TSE:4502 / NYSE:TAK] (“Takeda”) today announced that the pivotal Phase 3 trial of its dengue vaccine candidate met the primary efficacy endpoint. This first analysis of the Tetravalent Immunization against Dengue Efficacy Study...

Takeda Completes Acquisition of Shire, Becoming a Global, Values-Based, R&D-Driven Biopharmaceutical Leader -Wednesday 9 January 2019

8 months from deal announcement to deal close Strong shareholder support with high approval rates on Takeda (89.1%) and Shire (99.8%) Integration planning well underway (BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced the...

Takeda Notes Court Sanction of the Scheme of Arrangement with Respect to the Acquisition of Shire plc -Friday 4 January 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) notes Shire plc’s (“Shire”) announcement that the Royal Court of Jersey (the “Jersey Court”) has today sanctioned the scheme of arrangement (the “Scheme”) pursuant to which the proposed...

Takeda Announces Multiple Cell Therapy Collaborations to Advance the Company’s Novel Immuno-Oncology Portfolio -Friday 4 January 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502) today announced new research collaborations in immuno-oncology (I-O), an area of key strategic focus for the company. Through these collaborations, Takeda seeks to accelerate the discovery of next-generation...

Takeda Announces Listing of American Depositary Shares on the New York Stock Exchange -Thursday 20 December 2018

(BUSINESS WIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today...

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult... -Monday 17 December 2018

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin)...

Takeda and the New York Academy of Sciences Announce 2019 Innovators in Science Award Winners -Thursday 13 December 2018  

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited, (“Takeda”) (TSE:4502) and the New York Academy of Sciences announced today the Winners of the second annual Innovators in Science Award for their commitment to and excellence in regenerative medicine. The 2019 Winner of the Senior...

Takeda Shareholders Approve Resolutions Related to the Proposed Acquisition of Shire plc -Thursday 6 December 2018

(BUSINESS WIRE)-- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today...

Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating... -Wednesday 5 December 2018

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502) today announced that data from the Phase 3 randomized, TOURMALINE-MM3 study evaluating the effect of single-agent oral NINLARO™ (ixazomib) as a maintenance therapy in adult patients diagnosed with multiple myeloma who...

Takeda Announces Execution of Loan Agreement in Connection with Proposed Acquisition of Shire plc -Wednesday 5 December 2018

(BUSINESS WIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (TSE:4502) (the “Company or...

European Commission Approves ALUNBRIG® (brigatinib) for ALK+ Non-Small Cell Lung Cancer in Patients... -Thursday 29 November 2018

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission (EC) granted marketing authorization for ALUNBRIG (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small...

Takeda Receives Clearance from the European Commission for the Proposed Acquisition of Shire plc -Sunday 25 November 2018

(BUSINESS WIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (“Takeda”) announces that it has...

Takeda Announces Publication of Circular and Notice of Extraordinary General Meeting of Shareholders in Relation to the... -Wednesday 14 November 2018

(BUSINESS WIRE) -- Further to the announcement on May 8, 2018, by Takeda Pharmaceutical Company Limited (“Takeda” or the “Company”) regarding the proposed acquisition (the “Acquisition”) of Shire plc (“Shire”), Takeda announces the publication of a circular (the “Circular”)...

Takeda to Present Data During 60th American Society of Hematology Annual Meeting on Wide Array of Treatment Needs for... -Monday 5 November 2018

– Results from Phase 3 Studies Including TOURMALINE-MM3 Trial of NINLARO™ (ixazomib) as Post- Autologous Stem Cell Transplant Maintenance Therapy and ECHELON-2 Trial of ADCETRIS® (brentuximab vedotin) in Frontline CD30-Positive Peripheral T-Cell Lymphoma Featured in Oral Sessions...

Takeda Reports Second Quarter FY2018 Results -Thursday 1 November 2018

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue +4.2%, led by Growth Drivers, with growth in every region Underlying Revenue was solid at +4.2%, with continued strong momentum from Takeda's Growth Drivers (Gastroenterology, Oncology,...

Takeda Comments on Ongoing Phase 1 Review by the European Commission of the Proposed Acquisition of Shire plc -Sunday 28 October 2018

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today issued the following statement with regard to its discussions with the European Commission (“EC”) as part of its Phase 1 review of the proposed acquisition of Shire plc (“Shire”) announced on May 8,...